Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

ALEX Trial: Alectinib versus Crizotinib in Treatment-Naïve Advanced ALK-Positive NSCLC

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Researchers presented updated 5-year progression-free survival and overall survival data from a clinical trial evaluating the efficacy and safety of alectinib versus crizotinib in previously untreated patients with ALK-positive NSCLC.

Alectinib is a next-generation oral anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has demonstrated promising activity in the treatment of patients with ALK-positive non–small-cell lung cancer (NSCLC). ALEX is a global, randomized phase 3 trial evaluating the efficacy and safety of alectinib versus crizotinib in treatment-naïve patients with ALK-positive NSCLC. Study results at the primary data cutoff (February 9, 2017) showed significant improvement in progression-free survival (PFS) with alectinib compared with crizotinib. Researchers reported the updated 5-year PFS and overall survival (OS) data from the ALEX trial during the ESMO Virtual Congress 2020.

A total of 303 patients aged ≥18 years with untreated, stage IIIB/IV ALK-positive NSCLC and an Eastern Cooperative Oncology Group performance score of 0 to 2 were randomized to receive either alectinib 600 mg twice daily (N = 152) or crizotinib 250 mg twice daily (N = 151) until progressive disease, toxicity, withdrawal, or death. The primary end point was investigator-assessed PFS, and secondary end points included PFS as assessed by an independent review committee, objective response rate, OS, and safety.

The median duration of follow-up for investigator-assessed PFS was 48.2 months (range, 0.5-62.7 months) in the alectinib arm and 23.3 months (range, 0.3-60.6 months) in the crizotinib arm. Mature data demonstrated a significant improvement in median PFS with alectinib versus crizotinib (34.8 vs 10.9 months; stratified hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.32-0.58). The median duration of follow-up for OS was 48.2 months (range, 0.5-62.7 months) in the alectinib arm and 23.3 months (range, 0.3-60.6 months) in the crizotinib arm. The OS data remain immature, with 37% of events recorded. The median OS had not yet been reached with alectinib and was 57.4 months with crizotinib (stratified HR, 0.67; 95% CI, 0.46-0.98). The 5-year OS rate was 62.5% with alectinib versus 45.5% with crizotinib. At the time of analysis, 34.9% of patients in the alectinib arm and 8.6% of those in the crizotinib arm were still receiving the study treatment.

No new safety signals were reported. Grade ≥3 adverse events (AEs) occurred in 52.0% and 56.3% of patients in the alectinib and crizotinib arms, respectively. In the alectinib arm, the most common grade ≥3 AEs were anemia (5.9%), increased aspartate transaminase (AST; 5.3%), increased alanine aminotransferase (4.6%), and pneumonia (4.6%). In the crizotinib arm, the most common grade ≥3 AEs were increased alanine aminotransferase (15.9%), increased AST (10.6%), neutropenia (5.3%), and increased blood creatine phosphokinase (4.0%). Similar percentages of patients in the alectinib and crizotinib arms reported AEs leading to dose reductions (20.4% and 19.9%, respectively) and treatment discontinuations (14.5% and 14.6%, respectively).

The researchers stated that ALEX is the first global randomized study to demonstrate improvement of both PFS and OS using a next-generation ALK TKI compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.

Reference
Mok T, et al. Ann Oncol. 2020;31:1056-1064.

Related Items
NSCLC Year in Review Introduction
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Inhibition of VEGFR and EGFR with Apatinib + Gefitinib as First-Line Therapy Increased Progression-Free Survival
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
FLAURA Trial: Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Savolitinib Shows Potential for Patients with NSCLC and MET Exon 14 Skipping Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Poziotinib Shows Promise for Treating Patients with NSCLC and EGFR or HER2 Exon 20 Insertion Mutations
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
RELAY Results: Patients with Exon 21 L858R or Exon 19 Deletion Mutations of EGFR Benefit from Ramucirumab + Erlotinib
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: January 29, 2021